Gain Therapeutics Company Insiders
| GANX Stock | USD 1.59 0.02 1.24% |
Gain Therapeutics' insiders are aggressively buying. The analysis of the overall insider sentiment regarding Gain Therapeutics suggests that vertually all insiders are extremely bullish. Gain Therapeutics employs about 23 people. The company is managed by 13 executives with a total tenure of roughly 54 years, averaging almost 4.0 years of service per executive, having 1.77 employees per reported executive.
Insider Sentiment 100
Aggressively Buying
Selling | Buying |
Latest Trades
| 2024-08-09 | Khalid Islam | Acquired 50000 @ 1 | View |
Monitoring Gain Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gain Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. Gain Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.971) % which means that it has lost $0.971 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.9022) %, meaning that it created substantial loss on money invested by shareholders. Gain Therapeutics' management efficiency ratios could be used to measure how well Gain Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.79 in 2025. Return On Capital Employed is likely to rise to -2.35 in 2025. At this time, Gain Therapeutics' Total Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 15.4 M in 2025, whereas Net Tangible Assets are likely to drop slightly above 12.8 M in 2025.Common Stock Shares Outstanding is likely to drop to about 13.2 M in 2025. Net Loss is likely to rise to about (15 M) in 2025
Gain Therapeutics Workforce Comparison
Gain Therapeutics is rated # 4 in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 155. Gain Therapeutics retains roughly 23.0 in number of employees claiming about 15% of equities under Health Care industry.
Gain Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Gain Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Gain Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Gain Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Gain Therapeutics Notable Stakeholders
A Gain Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Gain Therapeutics often face trade-offs trying to please all of them. Gain Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Gain Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| LLM IUR | CEO President | Profile | |
| Khalid Islam | Executive Chairman | Profile | |
| Evan Ballantyne | CFO Secretary | Profile | |
| Gianluca Fuggetta | Principal Reporting | Profile | |
| Xavier Barril | Chief Officer | Profile | |
| Joanne Taylor | Senior Research | Profile | |
| Terenzio PharmD | Senior Operations | Profile | |
| Salvatore Calabrese | CFO Sec | Profile | |
| Jonas MD | Chief Officer | Profile | |
| Ana GarciaCollazo | Head Research | Profile | |
| Natalia PerezCarmona | Head Biology | Profile | |
| Manolo Bellotto | GM Officer | Profile | |
| Gene MBA | Chief Officer | Profile |
About Gain Therapeutics Management Performance
The success or failure of an entity such as Gain Therapeutics often depends on how effective the management is. Gain Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Gain management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Gain management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.70) | (1.79) | |
| Return On Capital Employed | (2.48) | (2.35) | |
| Return On Assets | (1.68) | (1.77) | |
| Return On Equity | (2.78) | (2.64) |
Please note, the imprecision that can be found in Gain Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Gain Therapeutics. Check Gain Therapeutics' Beneish M Score to see the likelihood of Gain Therapeutics' management manipulating its earnings.
Gain Therapeutics Workforce Analysis
Traditionally, organizations such as Gain Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Gain Therapeutics within its industry.Gain Therapeutics Manpower Efficiency
Return on Gain Therapeutics Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 887.4K | |
| Net Loss Per Executive | 1.6M | |
| Working Capital Per Employee | 334.4K | |
| Working Capital Per Executive | 591.6K |
Additional Tools for Gain Stock Analysis
When running Gain Therapeutics' price analysis, check to measure Gain Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gain Therapeutics is operating at the current time. Most of Gain Therapeutics' value examination focuses on studying past and present price action to predict the probability of Gain Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gain Therapeutics' price. Additionally, you may evaluate how the addition of Gain Therapeutics to your portfolios can decrease your overall portfolio volatility.